{"nctId":"NCT01863732","briefTitle":"Extension in AS: Sustainability of Benefits, Safety and Tolerability","startDateStruct":{"date":"2013-11-06","type":"ACTUAL"},"conditions":["Spondylitis, Ankylosing"],"count":274,"armGroups":[{"label":"Secukinumab (AIN457) 75mg Grp1","type":"EXPERIMENTAL","interventionNames":["Biological: Secukinumab","Other: Placebo (Pbo)"]},{"label":"Secukinumab (AIN457) 75 to 150mg Grp1","type":"EXPERIMENTAL","interventionNames":["Biological: Secukinumab","Other: Placebo (Pbo)"]},{"label":"Secukinumab (AIN457) 150mg Grp2","type":"EXPERIMENTAL","interventionNames":["Biological: Secukinumab","Other: Placebo (Pbo)"]},{"label":"Pbo in Core then AIN457 75mg Grp1","type":"EXPERIMENTAL","interventionNames":["Biological: Secukinumab","Other: Placebo (Pbo)"]},{"label":"Pbo in Core then AIN457 75 to 150mg Grp1","type":"EXPERIMENTAL","interventionNames":["Biological: Secukinumab","Other: Placebo (Pbo)"]},{"label":"Pbo in Core then AIN457 150mg Grp2","type":"EXPERIMENTAL","interventionNames":["Biological: Secukinumab","Other: Placebo (Pbo)"]}],"interventions":[{"name":"Secukinumab","otherNames":["AIN457"]},{"name":"Placebo (Pbo)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: patients having completed the \"core study\" CAIN457F2305, indication for treatment extension. -- Exclusion Criteria: history of hypersensitivity to secukinumab or to any drug of similar chemical classes, use of any investigational drug other than secukinumab during the \"core study\" CAIN457F2305.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Assessment of Spondyloarthritis International Society Criteria (ASAS) 20 Response From Week 104 to Week 260","description":"ASAS 20 response is a validated composite assessment, reflecting the proportion of treated patients who achieve within a defined time frame at least 20% improvement in score in at least 3 of a conventional set of 4 clinical domains relevant to AS and no worsening in the fourth domain. In this study, ASAS 20 is used to assess quantitatively the sustainability of clinical benefits of two dosage regimens of secukinumab over the treatment period from Week 104 to Week 260 No Statistical Analysis was performed This was the total for Group 1 Participants that up-titrated are counted only at the originally randomized treatment group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null},{"groupId":"OG001","value":"80.0","spread":null},{"groupId":"OG002","value":"78.6","spread":null},{"groupId":"OG003","value":"73.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":null},{"groupId":"OG001","value":"82.1","spread":null},{"groupId":"OG002","value":"76.1","spread":null},{"groupId":"OG003","value":"70.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.1","spread":null},{"groupId":"OG001","value":"77.1","spread":null},{"groupId":"OG002","value":"84.8","spread":null},{"groupId":"OG003","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.1","spread":null},{"groupId":"OG001","value":"75.0","spread":null},{"groupId":"OG002","value":"75.6","spread":null},{"groupId":"OG003","value":"72.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null},{"groupId":"OG001","value":"80.2","spread":null},{"groupId":"OG002","value":"76.1","spread":null},{"groupId":"OG003","value":"67.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.7","spread":null},{"groupId":"OG001","value":"78.3","spread":null},{"groupId":"OG002","value":"83.3","spread":null},{"groupId":"OG003","value":"78.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.7","spread":null},{"groupId":"OG001","value":"80.0","spread":null},{"groupId":"OG002","value":"81.0","spread":null},{"groupId":"OG003","value":"78.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.3","spread":null},{"groupId":"OG001","value":"84.8","spread":null},{"groupId":"OG002","value":"81.0","spread":null},{"groupId":"OG003","value":"73.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.4","spread":null},{"groupId":"OG001","value":"79.7","spread":null},{"groupId":"OG002","value":"75.0","spread":null},{"groupId":"OG003","value":"78.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":null},{"groupId":"OG001","value":"81.8","spread":null},{"groupId":"OG002","value":"81.1","spread":null},{"groupId":"OG003","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.7","spread":null},{"groupId":"OG001","value":"82.1","spread":null},{"groupId":"OG002","value":"75.7","spread":null},{"groupId":"OG003","value":"77.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.7","spread":null},{"groupId":"OG001","value":"82.1","spread":null},{"groupId":"OG002","value":"80.0","spread":null},{"groupId":"OG003","value":"76.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":null},{"groupId":"OG001","value":"77.6","spread":null},{"groupId":"OG002","value":"81.6","spread":null},{"groupId":"OG003","value":"80.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Spondyloarthritis International Society Criteria (ASAS) 40 Response From Week 104 to Week 260","description":"ASAS 40 response is a validated composite assessment, reflecting the proportion of treated patients who achieve within a defined time frame at least 40% improvement in score in at least 3 of a conventional set of 4 clinical domains relevant to AS and no worsening in the fourth domain. In this study, ASAS 40 is used to assess quantitatively the sustainability of clinical benefits of two dosage regimens of secukinumab over the treatment period from Week 104 to Week 260 No Statistical Analysis was performed This was the total for Group 1 Participants that up-titrated are counted only at the originally randomized treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6","spread":null},{"groupId":"OG001","value":"65.0","spread":null},{"groupId":"OG002","value":"57.1","spread":null},{"groupId":"OG003","value":"48.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":null},{"groupId":"OG001","value":"59.5","spread":null},{"groupId":"OG002","value":"54.3","spread":null},{"groupId":"OG003","value":"51.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.6","spread":null},{"groupId":"OG001","value":"68.7","spread":null},{"groupId":"OG002","value":"58.7","spread":null},{"groupId":"OG003","value":"55.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":null},{"groupId":"OG001","value":"60.7","spread":null},{"groupId":"OG002","value":"53.3","spread":null},{"groupId":"OG003","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"62.8","spread":null},{"groupId":"OG002","value":"54.3","spread":null},{"groupId":"OG003","value":"55.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7","spread":null},{"groupId":"OG001","value":"67.5","spread":null},{"groupId":"OG002","value":"42.9","spread":null},{"groupId":"OG003","value":"62.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.7","spread":null},{"groupId":"OG001","value":"68.8","spread":null},{"groupId":"OG002","value":"52.4","spread":null},{"groupId":"OG003","value":"67.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.4","spread":null},{"groupId":"OG001","value":"69.6","spread":null},{"groupId":"OG002","value":"52.4","spread":null},{"groupId":"OG003","value":"62.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.1","spread":null},{"groupId":"OG001","value":"60.8","spread":null},{"groupId":"OG002","value":"62.5","spread":null},{"groupId":"OG003","value":"56.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"67.5","spread":null},{"groupId":"OG002","value":"54.1","spread":null},{"groupId":"OG003","value":"63.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.2","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"59.5","spread":null},{"groupId":"OG003","value":"69.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":null},{"groupId":"OG001","value":"70.5","spread":null},{"groupId":"OG002","value":"62.9","spread":null},{"groupId":"OG003","value":"61.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.6","spread":null},{"groupId":"OG001","value":"64.5","spread":null},{"groupId":"OG002","value":"63.2","spread":null},{"groupId":"OG003","value":"66.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":179},"commonTop":["Nasopharyngitis","Diarrhoea","Headache","Upper respiratory tract infection","Influenza"]}}}